Zanubrutinib for treating marginal zone lymphoma

Zanubrutinib is currently in clinical development for treating relapsed or refractory marginal zone lymphoma (MZL). MZL is a rare group of non-Hodgkin’s lymphomas that affect a type of immune cell called B-cells. These MZLs are slow growing and do not always cause symptoms. Broad symptoms that do sometimes appear in MZL patients include unexplained weight loss, night sweats and fever. There are a limited number of treatment options available to MZL patients who are relapsed or refractory to initial treatment, and current treatments often result in adverse side-effects. Therefore, there is a need to develop additional treatment options for these patients.